Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGL-270 and PD-1/PD-L1 Inhibitors in Advanced NSCLC
NCT07652125Recruiting
- Sponsor
- Guangdong Association of Clinical Trials
- Start
- Oct 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Open-label trial of RGL-270 in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Guangdong Association of Clinical Trials. Primary endpoint: Safety Endpoints at 3 years. Started Oct 2025; status: recruiting.
02
Drugs
RGL-270
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07652125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07652125.